Telbivudine versus lamivudine in patients with chronic hepatitis B - Wikidata - wikimedia - TriplyDB

Telbivudine versus lamivudine in patients with chronic hepatitis B

Telbivudine versus lamivudine in patients with chronic hepatitis B

http://www.wikidata.org/entity/Q28261708

about

Antiviral drugs for viruses other than human immunodeficiency virus Clinical relevance and public health significance of hepatitis B virus genomic variations KASL clinical practice guidelines: management of chronic hepatitis B Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection Evolution of hepatitis B management in kidney transplantation Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis Direct acting antivirals for the treatment of chronic viral hepatitis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice Approved Antiviral Drugs over the Past 50 Years Current and future antiviral drug therapies of hepatitis B chronic infection rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options Safety and efficacy of telbivudine for the treatment of chronic hepatitis B Current hepatitis B treatment guidelines and future research directions.Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.Optimization therapy for the treatment of chronic hepatitis B Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women.Vertical transmission of hepatitis B virus: challenges and solutions A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review).Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Hepatitis B Therapy in Pregnancy Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.Antiviral treatment of chronic hepatitis B virus (HBV) infections Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice

P2860

Q24635330-49207897-7452-4A67-B4EC-A6655CD4E509 Q24644176-EE3C5173-209F-43EE-B197-EAA5F201DB5E Q26752475-10F6185B-C322-4B98-8938-550CA5C20251 Q26766014-068E744C-2645-4C19-88C0-529991FCB6F9 Q26781795-444923AF-2CEA-46F1-8D64-4CDC31670A4C Q26781962-DF303C86-0740-4766-8F16-CA2B7CC0C4E0 Q26995706-F4030E4C-1C56-4119-BF97-4FF68E065071 Q26995814-CD212597-6A8B-402F-8EE1-06657342BFA4 Q27000080-3B654DA2-5D78-40D9-9F64-F121ABB6CF59 Q27016075-0BC00558-5264-4663-9CE0-53891A4A1BEA Q27022216-BC74DA54-49AE-4E21-93E3-59BB743586BB Q27030828-ED69BFB9-62CF-4D1E-A3FF-1AD4A2086930 Q27488385-CA79E74E-D378-4055-9C61-5645F83D7C0A Q27755387-54CAEA62-F1BD-4A95-A175-38CC9D6511B7 Q28084820-234E46AD-E98F-4C2D-9362-BFCCD1945B85 Q28540082-D9529E1F-FB34-4EA6-8014-F98273AC52D6 Q28704122-0833D89C-C648-44B0-B947-E9BE61FD3000 Q28972486-50893D53-4380-44B9-B6E9-9CF33F715C63 Q30487002-6F922D66-B50A-4173-829E-7E296589FDAE Q30829485-4016E7E2-578C-418F-B6C5-E9F76842407C Q33626813-04834D55-8337-4763-AC8C-63E170CE5760 Q33676349-B67EB703-8DA9-4E41-96C0-A2CB5974D0D5 Q33711399-38847326-5CB2-4CEC-9FA3-17C0E5AD6A73 Q33774099-9C89AA78-D452-4ED4-9E40-D899D5EF832B Q33819098-15E62BF5-3618-4328-AD65-8326FF2871A3 Q33819124-F8B63C76-695B-435B-8789-737AE5D87A54 Q33826784-4E5B77FD-AE11-4454-A76B-E96BB44D1BC0 Q33848190-375B6AA0-21CD-403D-90E2-7655E343A339 Q33872988-581561BA-52D5-448A-99EC-D9C039EEAE8A Q33948393-185D4951-D897-4F57-9FFE-C45631DB2F73 Q34021608-6338407F-D235-4036-8B6E-668F6A9B185B Q34024728-D4B72915-6A0F-4107-A252-CF44305B880A Q34084987-229F3CAF-F52D-47AC-A42D-AE1AF2BFBB4D Q34120419-5BF7629E-4D90-4A82-972D-97E2C2DE98C2 Q34128296-9BF78BD2-CC93-4FD7-A4D0-915595B56DE8 Q34137291-6114DFDF-3CF1-4053-98C8-EFFAE16CB997 Q34154952-AC909A47-950E-4436-80C0-B20286715144 Q34168465-4C541F9D-4EA5-4956-A608-425CD7FBDBDF Q34223779-3D08A199-4CC5-43A9-A3C5-80697533F58C Q34256062-5B34F5CF-6163-40BD-8545-F4C1CD12806A

P2860

Telbivudine versus lamivudine in patients with chronic hepatitis B

http://www.wikidata.org/entity/Q28261708

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Telbivudine versus lamivudine in patients with chronic hepatitis B

@ast

Telbivudine versus lamivudine in patients with chronic hepatitis B

@en

Telbivudine versus lamivudine in patients with chronic hepatitis B

@nl

type

label

Telbivudine versus lamivudine in patients with chronic hepatitis B

@ast

Telbivudine versus lamivudine in patients with chronic hepatitis B

@en

Telbivudine versus lamivudine in patients with chronic hepatitis B

@nl

prefLabel

Telbivudine versus lamivudine in patients with chronic hepatitis B

@ast

Telbivudine versus lamivudine in patients with chronic hepatitis B

@en

Telbivudine versus lamivudine in patients with chronic hepatitis B

@nl

P1433

Q28261708-A0A00B36-ADDE-4858-9B58-36CBEFB9DD8B

P1476

Q28261708-B51B2B8C-46F6-4D34-A830-3F26AA3FD6F4

P2093

Q28261708-2B4693F1-63D3-4932-B0C6-C8D6A12A3340

Q28261708-392618FB-82FF-42F9-AB2A-1511846B1AC2

Q28261708-3A0A2061-0746-4A17-8325-455E56D9FEAE

Q28261708-4F0CFBA6-AD45-42AE-85AD-30F639BD754C

Q28261708-56E5B975-B6C5-453B-A40E-1DAE3244E545

Q28261708-5FA8A714-EBD5-4687-ADEE-6DAD7AA573F8

Q28261708-60639BA8-C3DA-49E4-A07F-BDA1ED11CA29

Q28261708-63D72232-B196-4950-A7B1-F1629EF75CA7

Q28261708-7912FB60-FF23-481B-B2EE-3E5F65A12BB2

Q28261708-7ECA3200-E1A4-4118-A6CB-AB28FAA12A29

P304

Q28261708-EBADC693-D4D3-43A0-90E1-E576991FBE36

P31

Q28261708-F12ED3EA-491C-40D9-8BC4-224C435298EA

P3181

Q28261708-3EF0D185-6B38-4B06-99F3-EEFD4E4DEAC9

P356

Q28261708-15B34A98-E03B-4992-83A9-32372763B8B9

P407

Q28261708-2DCA739D-E9D0-49A0-AC64-346D530E241B

P433

Q28261708-E7D591FB-E70C-448E-ACAB-C238A7C3F3E4

P478

Q28261708-2DB787C1-A3E2-4DC7-BA93-68CC3202683C

P50

Q28261708-59BAD31C-B641-474E-A892-92840DE2390B

Q28261708-5D47748C-073F-46D7-82A8-D8CACD3B148A

Q28261708-e0e3979a-4980-4f98-57ac-4db611800796

P577

Q28261708-D12D5DEB-C286-47A1-8B9A-FC36CCD192D8

P698

Q28261708-5A69A2D6-E96E-4611-BC54-042EB5EA66B9

P3181

P356

P1433

The New England Journal of Medicine

P1476

Telbivudine versus lamivudine in patients with chronic hepatitis B

@en

P2093

Barbara Fielman Constance

http://www.w3.org/2001/XMLSchema#string

Chao-Wei Hsu

http://www.w3.org/2001/XMLSchema#string

Ching-Lung Lai

http://www.w3.org/2001/XMLSchema#string

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

Edward Gane

http://www.w3.org/2001/XMLSchema#string

George Chao

http://www.w3.org/2001/XMLSchema#string

Jens Rasenack

http://www.w3.org/2001/XMLSchema#string

Natalie Bzowej

http://www.w3.org/2001/XMLSchema#string

Nathaniel A Brown

http://www.w3.org/2001/XMLSchema#string

Nikolai V Naoumov

http://www.w3.org/2001/XMLSchema#string

P304

2576-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2130287

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA066422

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P50

Adrian M. Di Bisceglie

P577

2007-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18094378

http://www.w3.org/2001/XMLSchema#string